A researcher discovers a new compound that inhibits the G1/S checkpoint in the cell cycle. Based on this information, which of the following would be a likely effect on the cell?

Core Concept

PILLAR 1 — MOLECULAR/CONCEPTUAL MECHANISM

Step-by-Step Analysis

The G1/S checkpoint, often termed the restriction point in mammalian somatic cells, functions as a molecular gatekeeper that evaluates whether internal and external conditions justify the metabolic commitment to DNA replication. This regulatory node operates through a cascade of cyclin-dependent kinase (CDK) complexes, principally cyclin D–CDK4/6 and cyclin E–CDK2. Under normal conditions, the retinoblastoma tumor suppressor protein (Rb) binds tightly to E2F transcription factors, physically occluding their transactivation domains and preventing transcription of S-phase genes such as DNA polymerase α, thymidine kinase, and dihydrofolate reductase. When growth factor ligands—epidermal growth factor (EGF), platelet-derived growth factor (PDGF), or fibroblast growth factor (FGF)—bind their respective receptor tyrosine kinases (RTKs) on the cell surface, the resulting autophosphorylation triggers the Ras–Raf–MEK–ERK intracellular signaling cascade. ERK phosphorylation upregulates cyclin D transcription, enabling cyclin D–CDK4/6 complexes to initiate Rb hyperphosphorylation. This phosphorylation induces a conformational change in Rb, reducing its affinity for E2F and releasing E2F to activate S-phase gene transcription. Additionally, the G1/S checkpoint monitors DNA integrity through the ATM/ATR kinase network. When double-strand breaks or replication stress are detected, ATM/ATR phosphorylate and stabilize p53, which transcriptionally activates p21 (CIP1/WAF1). The p21 protein competitively inhibits cyclin E–CDK2 by inserting into the ATP-binding cleft of the CDK catalytic subunit, halting Rb phosphorylation and arresting the cell before S-phase entry.

Why Other Options Are Wrong

Inhibiting the G1/S checkpoint dismantles this surveillance architecture. A compound that disables checkpoint function prevents the cell from pausing to verify adequate cell mass, nutrient availability, and genomic integrity before initiating DNA synthesis. The molecular consequence is premature and unchecked passage from G1 into S phase, eliminating the temporal delay normally imposed by the p53–p21–CDK inhibitory axis and the Rb–E2F gatekeeping mechanism.

PILLAR 2 — STEP-BY-STEP LOGIC

The question states that the compound specifically inhibits the G1/S checkpoint, meaning it blocks the regulatory barrier that restrains the G1-to-S phase transition. Without a functional G1/S checkpoint, the cell bypasses the restriction point and enters S phase without completing the standard duration of G1. DNA replication commences immediately, followed by progression through G2 and into mitotic prophase. Because G1 is the most variable phase in length among cycling cells—and is frequently the longest phase in eukaryotic cell cycles—eliminating the G1/S checkpoint effectively truncates the overall cell cycle duration. The cell reaches mitotic entry sooner than it would under normal checkpoint control, producing a shortened interphase-to-mitosis interval. Option A correctly captures this outcome: early mitotic entry resulting from checkpoint abrogation compresses the temporal span of the cell cycle.

This mechanism mirrors the action of mutations in tumor suppressor genes observed in cancer biology. Loss-of-function mutations in RB1 or TP53 eliminate checkpoint control precisely at G1/S, allowing relentless proliferative cycling—a hallmark of oncogenic transformation that underscores why G1/S checkpoint integrity matters for tissue homeostasis.

PILLAR 3 — DISTRACTOR ANALYSIS

Option B traps students who conflate different cell-cycle checkpoints. The G2/M checkpoint—regulated by the Chk1/Chk2 kinase-mediated inhibition of Cdc25 phosphatase and the subsequent failure to activate cyclin B–CDK1 (MPF)—controls mitotic entry from G2. Inhibiting the G1/S checkpoint has no direct bearing on G2/M checkpoint function; therefore, G2 arrest would not occur as a consequence of the described compound.

Option C appeals to students who associate checkpoint disruption with catastrophic outcomes. While severe DNA damage accumulating in checkpoint-deficient cells can eventually trigger mitochondrial cytochrome c release, apoptosome assembly, and caspase-9/caspase-3 activation, the immediate and direct consequence of G1/S checkpoint inhibition is accelerated cell-cycle progression, not apoptosis. The question asks for a likely primary effect, making apoptosis an indirect and secondary possibility at best.

Option D tempts students who misinterpret 'inhibit' as 'have no effect on' or who assume checkpoints are redundant systems whose loss goes unnoticed. The G1/S checkpoint actively restrains cell-cycle advancement; its inhibition removes a required regulatory brake, producing a detectable phenotypic change—accelerated cycling—rather than normal proliferation.